<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734474</url>
  </required_header>
  <id_info>
    <org_study_id>11422</org_study_id>
    <secondary_id>H9X-MC-GBCF</secondary_id>
    <secondary_id>CTRI/2009/091/000969</secondary_id>
    <nct_id>NCT00734474</nct_id>
  </id_info>
  <brief_title>A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin</brief_title>
  <official_title>A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United BioSource Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tessella Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berry Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects
      of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring
      glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type
      2 diabetes mellitus on Metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind study designed to select 1 or 2 LY2189265 doses for evaluation in
      Phase 3 studies (dose-finding portion) and to evaluate efficacy and safety of selected doses
      of LY2189265 in comparison to Sitagliptin (100 milligrams) up to 104 weeks and Placebo up to
      26 weeks in participants with type 2 diabetes mellitus on Metformin (confirmatory, Phase 3
      portion). The primary objective is to show non-inferiority of the higher LY2189265 dose (if 2
      doses are selected) to Sitagliptin with respect to change in glycosylated hemoglobin (HbA1c)
      at 52 weeks. The final endpoint is 104 weeks.

      Participants are randomized to receive Placebo, Sitagliptin, or 1 of 7 initial LY2189265
      doses until a dose decision is made based on quantitative analysis of the benefits and risks
      of each LY2189265 dose. A clinical utility index (CUI) that applies predicted values for
      change from baseline in HbA1c at 12 months and change from baseline in weight, diastolic
      blood pressure, and pulse rate at 6 months for each LY2189265 dose will be used toward this
      end. After the dose decision, participants in the selected LY2189265 arms and the comparator
      arms (Sitagliptin and Placebo/Sitagliptin arms) will continue the study, and additional
      participants will be randomized to the selected and comparator arms. Regardless of the timing
      of randomization relative to the dose decision point, all participants in the selected and
      comparator arms are planned to receive treatment for 104 weeks; participants in the
      Placebo/Sitagliptin arm will receive Placebo treatment for 26 weeks followed by Sitagliptin
      100 mg for 78 weeks for blinding purposes only, and participants in the selected and
      Sitagliptin arms will receive the same treatment for 104 weeks. All participants will remain
      blinded to their study treatment throughout the study. Participants in the non-selected arms
      will discontinue from the study after the dose decision
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Hemoglobin (HbA1c) Change From Baseline</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point</measure>
    <time_frame>Baseline up to 27.4 weeks</time_frame>
    <description>Change from baseline in HbA1c was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated Hemoglobin (HbA1c) Change From Baseline</measure>
    <time_frame>Baseline, 26 weeks, 104 weeks</time_frame>
    <description>Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of Change From Baseline in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, 13, 26, 52, and 104 weeks</time_frame>
    <description>Durability of effect on HbA1c was assessed by comparing the differences in mean change from baseline in HbA1c at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline HbA1c data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose Change From Baseline</measure>
    <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
    <description>Least squares (LS) means of change from baseline were calculated using mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin Change From Baseline</measure>
    <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
    <description>Least squares (LS) means of change from baseline fasting insulin data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Dose Decision Point</measure>
    <time_frame>Baseline up to 27.4 weeks</time_frame>
    <description>Change from baseline in body weight was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change From Baseline</measure>
    <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
    <description>Least squares (LS) means of change from baseline body weight were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of Change From Baseline Body Weight</measure>
    <time_frame>Baseline, 13, 26, 52, and 104 weeks</time_frame>
    <description>Durability of effect on body weight was assessed by comparing the differences in mean change from baseline in body weight at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline body weight data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference Change From Baseline</measure>
    <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
    <description>Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) &lt;7% or ≤6.5%</measure>
    <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
    <description>The percentage of participants achieving HbA1c levels &lt;7.0% and ≤6.5% was analyzed using a logistic regression model and last observation carried forward (LOCF) imputation with baseline, country, and treatment as factors included in the model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypoglycemic Episodes</measure>
    <time_frame>Baseline through 26 and 104 weeks</time_frame>
    <description>Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of participants with self-reported hypoglycemic events is summarized cumulatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hypoglycemic Episodes</measure>
    <time_frame>Baseline through 26 and 104 weeks</time_frame>
    <description>Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of HE is summarized cumulatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta Cell Function and Insulin Sensitivity (HOMA2)</measure>
    <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
    <description>The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-%B and HOMA2-%S were set at 100%. Least squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events at 26 Weeks</measure>
    <time_frame>Baseline through 26 weeks</time_frame>
    <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events at 52 Weeks</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events at 104 Weeks</measure>
    <time_frame>Baseline through 104 weeks</time_frame>
    <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 26 Weeks</measure>
    <time_frame>Baseline through 26 weeks</time_frame>
    <description>The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 52 Weeks</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 104 Weeks</measure>
    <time_frame>Baseline through 104 weeks</time_frame>
    <description>The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Abnormal Lipid Tests</measure>
    <time_frame>Baseline through 26 and 104 weeks</time_frame>
    <description>The number of participants with treatment-emergent abnormal lipid test (cholesterol, high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C], and triglycerides [TG]) results (defined as lipid test abnormalities that first occurred after baseline) is summarized cumulatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate at Dose Decision Point</measure>
    <time_frame>Baseline up to 27.4 weeks</time_frame>
    <description>Sitting pulse rate was measured at the time that the dose decision was made (dose decision point). Change from baseline in pulse rate was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure at Dose Decision Point</measure>
    <time_frame>Baseline up to 27.4 weeks</time_frame>
    <description>Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at the dose decision point. Change from baseline in DBP was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the time of the decision point was 27.4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline, 26 weeks, 104 weeks</time_frame>
    <description>Sitting and standing pulse rate were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline, 26 weeks, 104 weeks</time_frame>
    <description>Sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia-corrected QT (QTcF) and PR Interval</measure>
    <time_frame>Baseline, 26 weeks, 104 weeks</time_frame>
    <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant-reported Outcomes, Impact of Weight on Quality of Life-Lite (IWQoL-Lite)</measure>
    <time_frame>Baseline, 52 weeks, and 104 weeks</time_frame>
    <description>The Impact of Weight on Quality of Life-Lite (IWQoL-Lite questionnaire) is an obesity-specific, 31-item questionnaire designed to measure the impact of weight on participants' quality of life. Items are scored on a 5-point numeric rating scale where 5 = &quot;always true&quot; and 1 = &quot;never true&quot;. Items are summed into 6 scales (physical function [11 items], self-esteem [7 items], sexual life [4 items], public distress [5 items], work [4 items], and total score [31 items]) based on the average for the valid responses on that scale multiplied by the number of items on that scale (rounded to the nearest whole integer). Higher scores indicate lower levels of functioning (negative effects). Scores are linearly transformed to a 0 to 100 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant-reported Outcomes, EQ-5D</measure>
    <time_frame>Baseline, 52 weeks, and 104 weeks</time_frame>
    <description>The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts. The first part allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a three level scale of 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the questionnaire consists of a 100-millimeter visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization</measure>
    <time_frame>Baseline through 52 and 104 weeks</time_frame>
    <description>The number of visits to the emergency room (ER) is summarized cumulatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LY2189265: Area Under the Concentration-Time Curve</measure>
    <time_frame>Baseline through 52 weeks</time_frame>
    <description>Pharmacokinetic (PK) parameter estimates from LY2189265 concentration data were obtained using a 2-compartment population PK model with first order absorption. Area under the plasma-concentration curve from 0 to 168 hours, steady state (AUC0-168h, ss) of LY2189265 is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies to LY2189265</measure>
    <time_frame>Baseline through 104 weeks</time_frame>
    <description>The number of participants with postbaseline detection of treatment-emergent antidrug LY2189265 antibodies (ADA) is summarized.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Adjudicated Pancreatitis at 104 Weeks</measure>
    <time_frame>Baseline through 104 weeks</time_frame>
    <description>The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Adjudicated Cardiovascular Events at 104 Weeks</measure>
    <time_frame>Baseline through 104 weeks</time_frame>
    <description>Data on any new cardiovascular (CV) event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </other_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">1202</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>3.0 mg LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
Placebo: tablet, administered orally, once daily for up to 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.0 mg LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
Placebo: tablet, administered orally, once daily for up to 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
Placebo: tablet, administered orally, once daily for up to 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
Placebo: tablet, administered orally, once daily for up to 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.75 mg LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
Placebo: tablet, administered orally, once daily for up to 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
Placebo: tablet, administered orally, once daily for up to 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25 mg LY2189265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
Placebo: tablet, administered orally, once daily for up to 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Sitagliptin (Baseline Through 104 Weeks)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2189265</intervention_name>
    <arm_group_label>3.0 mg LY2189265</arm_group_label>
    <arm_group_label>2.0 mg LY2189265</arm_group_label>
    <arm_group_label>1.5 mg LY2189265</arm_group_label>
    <arm_group_label>1.0 mg LY2189265</arm_group_label>
    <arm_group_label>0.75 mg LY2189265</arm_group_label>
    <arm_group_label>0.5 mg LY2189265</arm_group_label>
    <arm_group_label>0.25 mg LY2189265</arm_group_label>
    <other_name>Dulaglutide</other_name>
    <other_name>Trulicity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo/Sitagliptin (Baseline Through 104 Weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <arm_group_label>3.0 mg LY2189265</arm_group_label>
    <arm_group_label>2.0 mg LY2189265</arm_group_label>
    <arm_group_label>1.5 mg LY2189265</arm_group_label>
    <arm_group_label>1.0 mg LY2189265</arm_group_label>
    <arm_group_label>0.75 mg LY2189265</arm_group_label>
    <arm_group_label>0.5 mg LY2189265</arm_group_label>
    <arm_group_label>0.25 mg LY2189265</arm_group_label>
    <arm_group_label>Placebo/Sitagliptin (Baseline Through 104 Weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>3.0 mg LY2189265</arm_group_label>
    <arm_group_label>2.0 mg LY2189265</arm_group_label>
    <arm_group_label>1.5 mg LY2189265</arm_group_label>
    <arm_group_label>1.0 mg LY2189265</arm_group_label>
    <arm_group_label>0.75 mg LY2189265</arm_group_label>
    <arm_group_label>0.5 mg LY2189265</arm_group_label>
    <arm_group_label>0.25 mg LY2189265</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo/Sitagliptin (Baseline Through 104 Weeks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus, type 2, for at least 6 months

          -  Treatment regimens: diet and exercise, metformin as monotherapy or in combination with
             another oral antihyperglycemic medication (OAM), or another OAM as monotherapy. Must
             be able to tolerate metformin at a dose of at least 1500 milligrams (mg) daily for 6
             weeks prior to randomization.

          -  Glycosylated hemoglobin (HbA1c) value of ≥7.0% to ≤9.5%, except participants on diet
             and exercise therapy who must have had HbA1c value of &gt;8.0% to ≤9.5%

          -  Body mass index (BMI) between 25 and 40 kilograms per meter squared (kg/m^2),
             inclusive

          -  Stable weight for 3 months prior to screening

          -  Females of childbearing potential must test negative for pregnancy and agree to use a
             reliable birth control method

        Exclusion Criteria:

          -  Diabetes mellitus, type 1

          -  Use of a glucagon-like peptide-1 (GLP-1) analog (for example, exenatide) within 6
             months prior to screening or are being treated with insulin

          -  Gastric emptying abnormality, history of bariatric surgery, or chronic use of drugs
             that affect gastrointestinal motility

          -  Use of medications to promote weight loss

          -  Clinically-relevant cardiovascular event within 6 months prior to screening

          -  Poorly controlled hypertension

          -  Electrocardiogram (ECG) reading considered outside the normal limits or indicating
             cardiac disease

          -  Liver disease, hepatitis, chronic pancreatitis, idiopathic acute pancreatitis, or
             alanine transaminase (ALT) levels &gt;3.0 times the upper limit of normal

          -  Serum creatinine ≥1.5 milligrams per deciliter (mg/dL) or a creatinine clearance &lt;60
             milliliters per minute (mL/minute)

          -  Uncontrolled diabetes, defined as &gt;2 episodes of ketoacidosis or hyperosmolar state
             requiring hospitalization in the 6 months prior to study entry.

          -  Uncontrolled endocrine or autoimmune abnormality

          -  History of a transplanted organ

          -  Chronic use of systemic glucocorticoid therapy

          -  Active or untreated malignancy

          -  Use of central nervous system (CNS) stimulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Chair</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <zip>04005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3P 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montpellier</city>
        <zip>F-34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Narbonne</city>
        <zip>11108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Mande</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toul</city>
        <zip>54201</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Venissieux</city>
        <zip>69200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Lauterberg</city>
        <zip>D-37431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Staffelstein</city>
        <zip>D-96231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bochum</city>
        <zip>D-44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>21073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hirschhorn</city>
        <zip>69434</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mainz</city>
        <zip>D-55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pohlheim</city>
        <zip>D-35415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rotenburg-Fulda</city>
        <zip>36199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangalore</city>
        <zip>560038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ghaziabad</city>
        <zip>201 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kochin</city>
        <zip>682026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pune</city>
        <zip>411005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goyang-Si</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seongnam-Si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>139-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sungnam-Si</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20129</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31238</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64461</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdynia</city>
        <zip>81-557</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>93-319</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-506</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-403</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baia Mare</city>
        <zip>430123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rostov-On-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dos Hermanas</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pozuelo De Alarcon</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiayi City</city>
        <zip>600</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yung-Kang, Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Hungary</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>(Lilly Clinical Trial Registry)</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <results_first_submitted>October 3, 2014</results_first_submitted>
  <results_first_submitted_qc>January 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2015</results_first_posted>
  <disposition_first_submitted>September 20, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 20, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 26, 2011</disposition_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes, type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dulaglutide</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3.0 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
        </group>
        <group group_id="P2">
          <title>2.0 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
        </group>
        <group group_id="P3">
          <title>1.5 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
        <group group_id="P4">
          <title>1.0 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
        </group>
        <group group_id="P5">
          <title>0.75 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
        <group group_id="P6">
          <title>0.5 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
        </group>
        <group group_id="P7">
          <title>0.25 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
        </group>
        <group group_id="P8">
          <title>Sitagliptin</title>
          <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
        <group group_id="P9">
          <title>Placebo/Sitagliptin</title>
          <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="304"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="302"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="24"/>
                <participants group_id="P8" count="315"/>
                <participants group_id="P9" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="304"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="302"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="24"/>
                <participants group_id="P8" count="315"/>
                <participants group_id="P9" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Study Before Dose Decision Point</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="24"/>
                <participants group_id="P8" count="42"/>
                <participants group_id="P9" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Up to Dose Decision Point</title>
              <participants_list>
                <participants group_id="P1" count="8">These participants discontinued the study after the dose decision point.</participants>
                <participants group_id="P2" count="25">These participants discontinued the study after the dose decision point.</participants>
                <participants group_id="P3" count="24">These participants continued the study after the dose decision point (selected arm).</participants>
                <participants group_id="P4" count="8">These participants discontinued the study after the dose decision point.</participants>
                <participants group_id="P5" count="21">These participants continued the study after the dose decision point (selected arm).</participants>
                <participants group_id="P6" count="21">These participants discontinued the study after the dose decision point.</participants>
                <participants group_id="P7" count="23">These participants discontinued the study after the dose decision point.</participants>
                <participants group_id="P8" count="42">These participants continued the study after the dose decision point (comparator arm).</participants>
                <participants group_id="P9" count="34">These participants continued the study after the dose decision point (comparator arm).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Study After Dose Decision Point</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="279"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="281"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="273"/>
                <participants group_id="P9" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 26-Week Visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="258"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="268"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="270"/>
                <participants group_id="P9" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 52-Week Visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="238"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="243"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="238"/>
                <participants group_id="P9" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="192"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="184"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="186"/>
                <participants group_id="P9" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="112"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="118"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="24"/>
                <participants group_id="P8" count="129"/>
                <participants group_id="P9" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="36"/>
                <participants group_id="P9" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="65"/>
                <participants group_id="P9" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision, Arm Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>3.0 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
        </group>
        <group group_id="B2">
          <title>2.0 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
        </group>
        <group group_id="B3">
          <title>1.5 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
        <group group_id="B4">
          <title>1.0 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
        </group>
        <group group_id="B5">
          <title>0.75 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
        <group group_id="B6">
          <title>0.5 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
        </group>
        <group group_id="B7">
          <title>0.25 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
        </group>
        <group group_id="B8">
          <title>Sitagliptin</title>
          <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
        <group group_id="B9">
          <title>Placebo/Sitagliptin</title>
          <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="304"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="302"/>
            <count group_id="B6" value="25"/>
            <count group_id="B7" value="24"/>
            <count group_id="B8" value="315"/>
            <count group_id="B9" value="177"/>
            <count group_id="B10" value="1202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.81" spread="10.66"/>
                    <measurement group_id="B2" value="52.56" spread="10.95"/>
                    <measurement group_id="B3" value="53.66" spread="10.02"/>
                    <measurement group_id="B4" value="55.38" spread="8.71"/>
                    <measurement group_id="B5" value="54.35" spread="9.81"/>
                    <measurement group_id="B6" value="54.70" spread="9.72"/>
                    <measurement group_id="B7" value="56.51" spread="6.56"/>
                    <measurement group_id="B8" value="53.75" spread="10.27"/>
                    <measurement group_id="B9" value="54.91" spread="9.05"/>
                    <measurement group_id="B10" value="54.09" spread="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="168"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="164"/>
                    <measurement group_id="B9" value="87"/>
                    <measurement group_id="B10" value="643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="134"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="151"/>
                    <measurement group_id="B9" value="90"/>
                    <measurement group_id="B10" value="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Aboriginal and/or Torres Strait Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="162"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="158"/>
                    <measurement group_id="B9" value="91"/>
                    <measurement group_id="B10" value="613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="52"/>
                    <measurement group_id="B9" value="28"/>
                    <measurement group_id="B10" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="67"/>
                    <measurement group_id="B9" value="38"/>
                    <measurement group_id="B10" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian (Indian sub-continent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="83"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="80"/>
                    <measurement group_id="B9" value="46"/>
                    <measurement group_id="B10" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="17"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="35"/>
                    <measurement group_id="B9" value="27"/>
                    <measurement group_id="B10" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="15"/>
                    <measurement group_id="B10" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="31"/>
                    <measurement group_id="B9" value="15"/>
                    <measurement group_id="B10" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.09" spread="14.25"/>
                    <measurement group_id="B2" value="86.56" spread="18.33"/>
                    <measurement group_id="B3" value="86.67" spread="17.45"/>
                    <measurement group_id="B4" value="89.48" spread="18.06"/>
                    <measurement group_id="B5" value="86.22" spread="17.99"/>
                    <measurement group_id="B6" value="88.84" spread="14.98"/>
                    <measurement group_id="B7" value="81.94" spread="17.67"/>
                    <measurement group_id="B8" value="85.97" spread="16.91"/>
                    <measurement group_id="B9" value="87.07" spread="16.86"/>
                    <measurement group_id="B10" value="86.38" spread="17.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.02" spread="4.69"/>
                    <measurement group_id="B2" value="31.45" spread="4.88"/>
                    <measurement group_id="B3" value="31.40" spread="4.57"/>
                    <measurement group_id="B4" value="33.89" spread="4.44"/>
                    <measurement group_id="B5" value="31.15" spread="4.44"/>
                    <measurement group_id="B6" value="32.53" spread="4.61"/>
                    <measurement group_id="B7" value="31.06" spread="3.94"/>
                    <measurement group_id="B8" value="31.02" spread="4.20"/>
                    <measurement group_id="B9" value="31.37" spread="4.25"/>
                    <measurement group_id="B10" value="31.27" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.95" spread="1.11"/>
                    <measurement group_id="B2" value="8.36" spread="1.04"/>
                    <measurement group_id="B3" value="8.12" spread="1.05"/>
                    <measurement group_id="B4" value="7.87" spread="0.62"/>
                    <measurement group_id="B5" value="8.19" spread="1.11"/>
                    <measurement group_id="B6" value="8.30" spread="1.34"/>
                    <measurement group_id="B7" value="7.82" spread="0.80"/>
                    <measurement group_id="B8" value="8.09" spread="1.09"/>
                    <measurement group_id="B9" value="8.10" spread="1.14"/>
                    <measurement group_id="B10" value="8.13" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.79" spread="6.34"/>
                    <measurement group_id="B2" value="6.92" spread="5.12"/>
                    <measurement group_id="B3" value="6.95" spread="5.50"/>
                    <measurement group_id="B4" value="7.04" spread="4.57"/>
                    <measurement group_id="B5" value="7.34" spread="4.92"/>
                    <measurement group_id="B6" value="6.75" spread="3.99"/>
                    <measurement group_id="B7" value="6.74" spread="4.20"/>
                    <measurement group_id="B8" value="7.16" spread="4.89"/>
                    <measurement group_id="B9" value="6.96" spread="5.43"/>
                    <measurement group_id="B10" value="7.09" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <units>millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Baseline fasting plasma glucose was not summarized for this treatment arm.</measurement>
                    <measurement group_id="B2" value="NA">Baseline fasting plasma glucose was not summarized for this treatment arm.</measurement>
                    <measurement group_id="B3" value="9.75" spread="3.27"/>
                    <measurement group_id="B4" value="NA">Baseline fasting plasma glucose was not summarized for this treatment arm.</measurement>
                    <measurement group_id="B5" value="9.68" spread="2.94"/>
                    <measurement group_id="B6" value="NA">Baseline fasting plasma glucose was not summarized for this treatment arm.</measurement>
                    <measurement group_id="B7" value="NA">Baseline fasting plasma glucose was not summarized for this treatment arm.</measurement>
                    <measurement group_id="B8" value="9.56" spread="2.80"/>
                    <measurement group_id="B9" value="9.86" spread="3.15"/>
                    <measurement group_id="B10" value="NA">Total Mean (SD) were not calculated for this baseline measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycosylated Hemoglobin (HbA1c) Change From Baseline</title>
        <description>Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms who had evaluable HbA1c data. Last observation carried forward was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c) Change From Baseline</title>
          <description>Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms who had evaluable HbA1c data. Last observation carried forward was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="297"/>
                <count group_id="O3" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="0.06"/>
                    <measurement group_id="O2" value="-0.87" spread="0.06"/>
                    <measurement group_id="O3" value="-0.39" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Power was estimated at approximately 89% based on a simulation study using the “most likely” pharmacodynamic model, assuming a 20% drop out rate (missing completely at random) at 52 weeks and enrollment of 5 participants per week. A predictive power calculation was planned to select either 263 or 333 as the minimum total sample size needed (sum of Stage 1 and 2) per arm. If the predictive power of the higher LY2189265 dose based on 263 participants in total exceeded 85%, then 263 would be used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Family-wise Type I error rate was controlled by applying gatekeeping strategies.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Power was estimated at approximately 89% based on a simulation study using the “most likely” pharmacodynamic model, assuming a 20% drop out rate (missing completely at random) at 52 weeks and enrollment of 5 participants per week. A predictive power calculation was planned to select either 263 or 333 as the minimum total sample size needed (sum of Stage 1 and 2) per arm. If the predictive power of the higher LY2189265 dose based on 263 participants in total exceeded 85%, then 263 would be used.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Family-wise Type I error rate was controlled by applying a gatekeeping strategy.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point</title>
        <description>Change from baseline in HbA1c was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.</description>
        <time_frame>Baseline up to 27.4 weeks</time_frame>
        <population>All participants randomized before the dose decision point who had evaluable HbA1c data.</population>
        <group_list>
          <group group_id="O1">
            <title>3.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
          </group>
          <group group_id="O2">
            <title>2.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>1.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O8">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point</title>
          <description>Change from baseline in HbA1c was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.</description>
          <population>All participants randomized before the dose decision point who had evaluable HbA1c data.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.77"/>
                    <measurement group_id="O2" value="-1.25" spread="0.68"/>
                    <measurement group_id="O3" value="-1.49" spread="1.12"/>
                    <measurement group_id="O4" value="-0.98" spread="0.47"/>
                    <measurement group_id="O5" value="-1.02" spread="0.99"/>
                    <measurement group_id="O6" value="-0.94" spread="0.65"/>
                    <measurement group_id="O7" value="-0.70" spread="0.49"/>
                    <measurement group_id="O8" value="-0.76" spread="0.86"/>
                    <measurement group_id="O9" value="-0.06" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycosylated Hemoglobin (HbA1c) Change From Baseline</title>
        <description>Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.</description>
        <time_frame>Baseline, 26 weeks, 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable HbA1c data. Last observation carried forward was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c) Change From Baseline</title>
          <description>Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable HbA1c data. Last observation carried forward was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="297"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="0.05"/>
                    <measurement group_id="O2" value="-1.01" spread="0.06"/>
                    <measurement group_id="O3" value="-0.61" spread="0.05"/>
                    <measurement group_id="O4" value="0.03" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="0.06"/>
                    <measurement group_id="O2" value="-0.71" spread="0.07"/>
                    <measurement group_id="O3" value="-0.32" spread="0.06"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 26 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.42</ci_lower_limit>
            <ci_upper_limit>-1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 26 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>-0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 26 weeks. One-sided raw p-value with no adjustment for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Family-wise Type I error rate was controlled by applying a gatekeeping strategy.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 104 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Family-wise Type I error rate controlled by applying gatekeeping strategy.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 104 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 104 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 104 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Durability of Change From Baseline in Glycosylated Hemoglobin (HbA1c)</title>
        <description>Durability of effect on HbA1c was assessed by comparing the differences in mean change from baseline in HbA1c at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline HbA1c data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 13, 26, 52, and 104 weeks</time_frame>
        <population>All participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms randomized after the dose decision point who had evaluable HbA1c data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Durability of Change From Baseline in Glycosylated Hemoglobin (HbA1c)</title>
          <description>Durability of effect on HbA1c was assessed by comparing the differences in mean change from baseline in HbA1c at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline HbA1c data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
          <population>All participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms randomized after the dose decision point who had evaluable HbA1c data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="314"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 Weeks Versus 13 Weeks (n=269, 269, 276, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.04"/>
                    <measurement group_id="O2" value="0.02" spread="0.04"/>
                    <measurement group_id="O3" value="0.00" spread="0.04"/>
                    <measurement group_id="O4" value="-0.14" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks Versus 26 Weeks (n=245, 254, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.05"/>
                    <measurement group_id="O2" value="0.16" spread="0.05"/>
                    <measurement group_id="O3" value="0.24" spread="0.05"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 Weeks Versus 52 Weeks (n=194, 191, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.06"/>
                    <measurement group_id="O2" value="0.16" spread="0.06"/>
                    <measurement group_id="O3" value="0.09" spread="0.06"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Glucose Change From Baseline</title>
        <description>Least squares (LS) means of change from baseline were calculated using mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable fasting plasma glucose data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Glucose Change From Baseline</title>
          <description>Least squares (LS) means of change from baseline were calculated using mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable fasting plasma glucose data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="308"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 Weeks (n=265, 271, 276, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="0.12"/>
                    <measurement group_id="O2" value="-1.97" spread="0.12"/>
                    <measurement group_id="O3" value="-0.97" spread="0.11"/>
                    <measurement group_id="O4" value="-0.49" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks (n=239, 247, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="0.13"/>
                    <measurement group_id="O2" value="-1.63" spread="0.13"/>
                    <measurement group_id="O3" value="-0.90" spread="0.13"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 Weeks (n=190, 187, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="0.15"/>
                    <measurement group_id="O2" value="-1.39" spread="0.15"/>
                    <measurement group_id="O3" value="-0.47" spread="0.15"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Comparison at 26 weeks.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>-1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.85</ci_lower_limit>
            <ci_upper_limit>-1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.82</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 104 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.93</ci_lower_limit>
            <ci_upper_limit>-1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 104 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin Change From Baseline</title>
        <description>Least squares (LS) means of change from baseline fasting insulin data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
        <population>All participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms randomized after the dose decision point who had evaluable fasting insulin data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin Change From Baseline</title>
          <description>Least squares (LS) means of change from baseline fasting insulin data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
          <population>All participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms randomized after the dose decision point who had evaluable fasting insulin data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>picomoles per liter (pmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 Weeks (n=238, 249, 230, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.59" spread="6.57"/>
                    <measurement group_id="O2" value="10.15" spread="6.51"/>
                    <measurement group_id="O3" value="8.48" spread="6.68"/>
                    <measurement group_id="O4" value="-6.92" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks (n=207, 218, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.57" spread="5.95"/>
                    <measurement group_id="O2" value="12.95" spread="5.88"/>
                    <measurement group_id="O3" value="4.18" spread="6.01"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 Weeks (n=187, 200, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.36" spread="7.58"/>
                    <measurement group_id="O2" value="21.56" spread="7.40"/>
                    <measurement group_id="O3" value="0.29" spread="7.64"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.095</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>18.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.25</ci_lower_limit>
            <ci_upper_limit>40.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.121</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>17.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.54</ci_lower_limit>
            <ci_upper_limit>38.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.167</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>15.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.47</ci_lower_limit>
            <ci_upper_limit>37.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.430</p_value>
            <p_value_desc>Comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.49</ci_lower_limit>
            <ci_upper_limit>22.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>Comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.94</ci_lower_limit>
            <ci_upper_limit>24.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.291</p_value>
            <p_value_desc>Comparison at 104 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>11.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.49</ci_lower_limit>
            <ci_upper_limit>31.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>Comparison at 104 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>21.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>41.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Dose Decision Point</title>
        <description>Change from baseline in body weight was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.</description>
        <time_frame>Baseline up to 27.4 weeks</time_frame>
        <population>All participants randomized before the dose decision point who had evaluable body weight data.</population>
        <group_list>
          <group group_id="O1">
            <title>3.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
          </group>
          <group group_id="O2">
            <title>2.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>1.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O8">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Dose Decision Point</title>
          <description>Change from baseline in body weight was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.</description>
          <population>All participants randomized before the dose decision point who had evaluable body weight data.</population>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="35"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.32" spread="3.37"/>
                    <measurement group_id="O2" value="-2.15" spread="1.97"/>
                    <measurement group_id="O3" value="-2.12" spread="1.93"/>
                    <measurement group_id="O4" value="-2.23" spread="1.63"/>
                    <measurement group_id="O5" value="-1.17" spread="2.30"/>
                    <measurement group_id="O6" value="-1.53" spread="1.88"/>
                    <measurement group_id="O7" value="-0.85" spread="1.47"/>
                    <measurement group_id="O8" value="-0.43" spread="1.78"/>
                    <measurement group_id="O9" value="-0.56" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change From Baseline</title>
        <description>Least squares (LS) means of change from baseline body weight were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable body weight data. Last observation carried forward was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight Change From Baseline</title>
          <description>Least squares (LS) means of change from baseline body weight were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline as a covariate.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable body weight data. Last observation carried forward was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>kilograms (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="299"/>
                <count group_id="O3" value="314"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="0.18"/>
                    <measurement group_id="O2" value="-2.63" spread="0.19"/>
                    <measurement group_id="O3" value="-1.46" spread="0.18"/>
                    <measurement group_id="O4" value="-1.47" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.03" spread="0.22"/>
                    <measurement group_id="O2" value="-2.60" spread="0.23"/>
                    <measurement group_id="O3" value="-1.53" spread="0.22"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.88" spread="0.25"/>
                    <measurement group_id="O2" value="-2.39" spread="0.26"/>
                    <measurement group_id="O3" value="-1.75" spread="0.25"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>-1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.73</ci_lower_limit>
            <ci_upper_limit>-0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.953</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 52 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.08</ci_lower_limit>
            <ci_upper_limit>-0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 52 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.65</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 104 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.78</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <p_value_desc>Comparison at 104 weeks.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Durability of Change From Baseline Body Weight</title>
        <description>Durability of effect on body weight was assessed by comparing the differences in mean change from baseline in body weight at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline body weight data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 13, 26, 52, and 104 weeks</time_frame>
        <population>All participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms randomized after the dose decision point who had evaluable body weight data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Durability of Change From Baseline Body Weight</title>
          <description>Durability of effect on body weight was assessed by comparing the differences in mean change from baseline in body weight at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline body weight data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
          <population>All participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms randomized after the dose decision point who had evaluable body weight data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>kilograms (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 Weeks Versus 13 Weeks (n=271, 278, 282, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.14"/>
                    <measurement group_id="O2" value="-0.57" spread="0.14"/>
                    <measurement group_id="O3" value="-0.42" spread="0.13"/>
                    <measurement group_id="O4" value="-0.37" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks Versus 26 Weeks (n=246, 255, 253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.18"/>
                    <measurement group_id="O2" value="0.06" spread="0.18"/>
                    <measurement group_id="O3" value="-0.04" spread="0.18"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 Weeks Versus 26 Weeks (n=197, 192, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.23"/>
                    <measurement group_id="O2" value="0.32" spread="0.24"/>
                    <measurement group_id="O3" value="-0.39" spread="0.23"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference Change From Baseline</title>
        <description>Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable waist circumference data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference Change From Baseline</title>
          <description>Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable waist circumference data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>centimeters (cm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="301"/>
                <count group_id="O3" value="312"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>26 Weeks (n=266, 273, 277, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="0.24"/>
                    <measurement group_id="O2" value="-1.78" spread="0.24"/>
                    <measurement group_id="O3" value="-1.45" spread="0.24"/>
                    <measurement group_id="O4" value="-1.20" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 Weeks (n=238, 250, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.91" spread="0.29"/>
                    <measurement group_id="O2" value="-2.05" spread="0.29"/>
                    <measurement group_id="O3" value="-1.45" spread="0.29"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 Weeks (n=192, 189, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" spread="0.35"/>
                    <measurement group_id="O2" value="-1.75" spread="0.35"/>
                    <measurement group_id="O3" value="-1.20" spread="0.35"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.45</ci_lower_limit>
            <ci_upper_limit>-0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.34</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.512</p_value>
            <p_value_desc>Comparison at 26 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.23</ci_lower_limit>
            <ci_upper_limit>-0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <p_value_desc>Comparison at 52 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.36</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Comparison at 104 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.256</p_value>
            <p_value_desc>Comparison at 104 weeks.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) &lt;7% or ≤6.5%</title>
        <description>The percentage of participants achieving HbA1c levels &lt;7.0% and ≤6.5% was analyzed using a logistic regression model and last observation carried forward (LOCF) imputation with baseline, country, and treatment as factors included in the model.</description>
        <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable HbA1c data. Last observation carried forward was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) &lt;7% or ≤6.5%</title>
          <description>The percentage of participants achieving HbA1c levels &lt;7.0% and ≤6.5% was analyzed using a logistic regression model and last observation carried forward (LOCF) imputation with baseline, country, and treatment as factors included in the model.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable HbA1c data. Last observation carried forward was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="297"/>
                <count group_id="O3" value="312"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;7.0% at 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9"/>
                    <measurement group_id="O2" value="55.2"/>
                    <measurement group_id="O3" value="37.8"/>
                    <measurement group_id="O4" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7.0% at 52 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6"/>
                    <measurement group_id="O2" value="48.8"/>
                    <measurement group_id="O3" value="33.0"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7.0% at 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3"/>
                    <measurement group_id="O2" value="44.8"/>
                    <measurement group_id="O3" value="31.1"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤6.5% at 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="31.0"/>
                    <measurement group_id="O3" value="21.8"/>
                    <measurement group_id="O4" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤6.5% at 52 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="29.0"/>
                    <measurement group_id="O3" value="19.2"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤6.5% at 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1"/>
                    <measurement group_id="O2" value="24.2"/>
                    <measurement group_id="O3" value="14.1"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c &lt;7.0% at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.8</ci_lower_limit>
            <ci_upper_limit>18.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c &lt;7.0% at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.2</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c &lt;7.0% at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c &lt;7.0% at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.7</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c &lt;7.0% at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c &lt;7.0% at 104 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c &lt;7.0% at 104 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c ≤6.5% at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c ≤6.5% at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Comparison of HbA1c ≤6.5 at 26 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c ≤6.5% at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c ≤6.5% at 52 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c ≤6.5% at 104 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.4</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparison of HbA1c ≤6.5% at 104 weeks.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypoglycemic Episodes</title>
        <description>Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of participants with self-reported hypoglycemic events is summarized cumulatively.</description>
        <time_frame>Baseline through 26 and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypoglycemic Episodes</title>
          <description>Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of participants with self-reported hypoglycemic events is summarized cumulatively.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hypoglycemic Episodes</title>
        <description>Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of HE is summarized cumulatively.</description>
        <time_frame>Baseline through 26 and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hypoglycemic Episodes</title>
          <description>Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of HE is summarized cumulatively.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms.</population>
          <units>episodes per participant per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.5"/>
                    <measurement group_id="O2" value="0.1" spread="0.9"/>
                    <measurement group_id="O3" value="0.1" spread="0.7"/>
                    <measurement group_id="O4" value="0.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented Symptomatic HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.9"/>
                    <measurement group_id="O2" value="0.2" spread="1.9"/>
                    <measurement group_id="O3" value="0.2" spread="1.4"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.8"/>
                    <measurement group_id="O2" value="0.1" spread="0.5"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymptomatic HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                    <measurement group_id="O2" value="0.0" spread="0.2"/>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.9"/>
                    <measurement group_id="O2" value="0.1" spread="0.6"/>
                    <measurement group_id="O3" value="0.0" spread="0.4"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.0" spread="0.2"/>
                    <measurement group_id="O3" value="0.1" spread="0.5"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable Symptomatic HE, 26 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.4"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable Symptomatic HE, 104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta Cell Function and Insulin Sensitivity (HOMA2)</title>
        <description>The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-%B and HOMA2-%S were set at 100%. Least squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26, 52, and 104 weeks</time_frame>
        <population>All participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms randomized after the dose decision point and who had evaluable HOMA2 data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Beta Cell Function and Insulin Sensitivity (HOMA2)</title>
          <description>The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-%B and HOMA2-%S were set at 100%. Least squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
          <population>All participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms randomized after the dose decision point and who had evaluable HOMA2 data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>HOMA2-%</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HOMA2-%B, 26 Weeks (n=206, 226, 206, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.28" spread="2.67"/>
                    <measurement group_id="O2" value="26.98" spread="2.60"/>
                    <measurement group_id="O3" value="10.81" spread="2.66"/>
                    <measurement group_id="O4" value="1.60" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA2-%B, 52 Weeks (n=188, 198, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.57" spread="2.51"/>
                    <measurement group_id="O2" value="22.30" spread="2.47"/>
                    <measurement group_id="O3" value="6.66" spread="2.53"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA2-%B, 104 Weeks (n=148, 154, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.89" spread="3.05"/>
                    <measurement group_id="O2" value="19.11" spread="3.00"/>
                    <measurement group_id="O3" value="1.47" spread="3.15"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA2-%S, 26 Weeks (n=206, 226, 206, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="2.34"/>
                    <measurement group_id="O2" value="0.78" spread="2.28"/>
                    <measurement group_id="O3" value="2.29" spread="2.33"/>
                    <measurement group_id="O4" value="9.82" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA2-%S, 52 Weeks (n=188, 198, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" spread="2.35"/>
                    <measurement group_id="O2" value="2.28" spread="2.32"/>
                    <measurement group_id="O3" value="4.25" spread="2.37"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOMA2-%S, 104 Weeks (n=148, 154, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="3.00"/>
                    <measurement group_id="O2" value="-0.12" spread="2.95"/>
                    <measurement group_id="O3" value="5.61" spread="3.11"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for participants who received Placebo at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events at 26 Weeks</title>
        <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 26 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events at 26 Weeks</title>
          <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="204"/>
                    <measurement group_id="O3" value="185"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events at 52 Weeks</title>
        <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>All randomized participants in the LY2189265 and active comparator (Sitagliptin) arms.</population>
        <group_list>
          <group group_id="O1">
            <title>3.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
          </group>
          <group group_id="O2">
            <title>2.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>1.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O8">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events at 52 Weeks</title>
          <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>All randomized participants in the LY2189265 and active comparator (Sitagliptin) arms.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="302"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="233"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="231"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events at 104 Weeks</title>
        <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events at 104 Weeks</title>
          <description>A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="255"/>
                    <measurement group_id="O3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 26 Weeks</title>
        <description>The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).</description>
        <time_frame>Baseline through 26 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms with baseline value not in the specified direction of treatment-emergent abnormality and at least 1 postbaseline result.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 26 Weeks</title>
          <description>The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms with baseline value not in the specified direction of treatment-emergent abnormality and at least 1 postbaseline result.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline Phosphatase (n=276, 258, 281, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/SGPT (n=232, 237, 244, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase Pancreatic, High (n=283, 277, 295, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase Total (n=266, 265, 277, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/SGOT (n=273, 269, 284, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, High (n=268, 259, 278, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Low (n=269, 259, 278, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Direct, High (n=295, 291, 307, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Total, High (n=295, 290, 305, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcitonin, High (n=226, 233, 230, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, High (n=299, 293, 310, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Low (n=299, 293, 308, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPK, High (n=273, 262, 276, 156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, High (n=294, 285, 303, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance, High (n=164, 186, 180, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance, Low (n=292, 278,303,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, High (n=258, 256, 275, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Low (n=269, 259, 278, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocyte Count, High (n=279, 272, 287, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocyte Count, Low (n=274, 268, 280, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, High (n=234, 240, 245, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, High (n=273, 265, 279, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, Low (n=256, 242, 259, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, High (n=278, 271, 289, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Low (n=262, 249, 265, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Count, High (n=272, 265, 286, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Count, Low (n=272, 262, 280, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, High (n=255, 248, 269, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, High (n=249, 253, 269, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Low (n=265, 258, 273, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, High (n=274, 265, 280, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Low (n=273, 263, 279, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV, High (n=261, 248, 263, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV, Low (n=264, 252, 275, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, High (n=266, 258, 274, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Low (n=265, 255, 274, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, High (n=264, 255, 276, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Low (n=263, 251, 271, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count, High (n=265, 260, 281, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count, Low (n=262, 252, 269, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, High (n=297, 291, 307, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Low (n=298, 293, 308, 169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, High (n=291, 291, 307, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Low (n=298, 292, 305, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen, High (n=287, 282, 305, 169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UMCR, High (n=217, 204, 232, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 52 Weeks</title>
        <description>The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR) .</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms with baseline value not in the specified direction of treatment-emergent abnormality and at least 1 postbaseline result.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 52 Weeks</title>
          <description>The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR) .</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms with baseline value not in the specified direction of treatment-emergent abnormality and at least 1 postbaseline result.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline Phosphatase, High (n=276, 258, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/SGPT, High (n=232, 237, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase Pancreatic, High (n=283, 277, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase Total, High (n=266, 265, 277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/SGOT, High (n=273, 269, 284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, High (n=276, 268, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Low (n=277, 268, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Direct, High (n=295, 291, 307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Total, High (n=295, 290, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcitonin, High (n=233, 239, 235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, High (n=299, 293, 310)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Low (n=299, 293, 308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPK, High (n=273, 262, 276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, High (n=294, 285, 303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance, High (n=164, 186, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance, Low (n=292, 278, 303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, High (n=265, 265, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Low (n=277, 268, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocyte Count, High (n=283, 276, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocyte Count, Low (n=278, 272, 285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, High (n=234, 240, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, High (n=280, 274, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, Low (n=262, 251, 269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, High (n=282, 275, 294)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Low (n=265, 253, 269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Count, High (n=277, 270, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Count, Low (n=277, 267, 284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, High (n=255, 248, 269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, High (n=257, 262, 278)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Low (n=273, 266, 280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, High (n=281, 274, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Low (n=280, 272, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV, High (n=267, 256, 273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV, Low (n=270, 261, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, High (n=274, 267, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Low (n=271, 264, 282)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, High (n=272, 263, 285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Low (n=271, 260, 279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count, High (n=272, 267, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count, Low (n=269, 259, 275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, High (n=297, 291, 307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Low (n=298, 293, 308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, High (n=291, 291, 307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Low (n=298, 292, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen, High (n=287, 282, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UMCR, High (n=223, 212, 238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 104 Weeks</title>
        <description>The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).</description>
        <time_frame>Baseline through 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms with baseline value not in the specified direction of treatment-emergent abnormality and at least 1 postbaseline result.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 104 Weeks</title>
          <description>The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms with baseline value not in the specified direction of treatment-emergent abnormality and at least 1 postbaseline result.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline Phosphate, High (n=276, 258, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/SGPT, High (n=232, 237, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase Pancreatic, High (n=283, 277, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase Total, High (n=266, 265, 277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/SGOT, High (n=273, 269, 284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, High (n=276, 268, 288)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Low (n=277, 268, 288)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Direct, High (n=295, 291, 307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Total, High (n=295, 290, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcitonin, High (n=233, 239, 235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, High (n=299, 293, 310)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Low (n=299, 293, 308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPK, High (n=273, 262, 276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, High (n=294, 285, 303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance, High (n=164, 186, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance, Low (n=292, 278, 303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, High (n=265, 265, 284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Low (n=277, 268, 288)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocyte Count, High (n=283, 276, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocyte Count, Low (n=278, 272, 285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, High (n=234, 240, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, High (n=280, 274, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, Low (n=262, 251, 269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, High (n=282, 275, 294)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Low (n=265, 253, 269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Count, High (n=277, 270, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Count, Low (n=277, 267, 284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, High (n=255, 248, 269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, High (n=257, 262, 279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Low (n=273, 266, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, High (n=281, 274, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Low (n=280, 272, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV, High (n=267, 256, 273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV, Low (n=270, 261, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, High (n=274, 267, 284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Low (n=271, 264, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, High (n=272, 263, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, Low (n=271, 260, 280)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count, High (n=273, 268, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count, Low (n=270, 260, 275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, High (n=297, 291, 307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Low (n=298, 293, 308)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, High (n=291, 291, 307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Low (n=298, 292, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea Nitrogen, High (n=287, 282, 305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UMCR, High (n=223, 212, 239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Abnormal Lipid Tests</title>
        <description>The number of participants with treatment-emergent abnormal lipid test (cholesterol, high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C], and triglycerides [TG]) results (defined as lipid test abnormalities that first occurred after baseline) is summarized cumulatively.</description>
        <time_frame>Baseline through 26 and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms with baseline value not in the specified direction of treatment-emergent abnormality and at least 1 postbaseline result.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Abnormal Lipid Tests</title>
          <description>The number of participants with treatment-emergent abnormal lipid test (cholesterol, high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C], and triglycerides [TG]) results (defined as lipid test abnormalities that first occurred after baseline) is summarized cumulatively.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms with baseline value not in the specified direction of treatment-emergent abnormality and at least 1 postbaseline result.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol, High, 26 Weeks (n=144, 158, 139, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol, High, 104 Weeks (n=151, 164, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, High, 26 Weeks (n=197, 201, 189, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, Low, 26 Weeks (n=127, 137, 129, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, High, 104 Weeks (n=206, 212, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, Low, 104 Weeks (n=134, 143, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C, High, 26 Weeks (n=155, 163, 150, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C, High, 104 Weeks (n=163, 170, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG, High, 26 Weeks (n=163, 174, 156, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG, High, 104 Weeks (n=170, 183, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate at Dose Decision Point</title>
        <description>Sitting pulse rate was measured at the time that the dose decision was made (dose decision point). Change from baseline in pulse rate was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.</description>
        <time_frame>Baseline up to 27.4 weeks</time_frame>
        <population>All participants randomized before the dose decision point who had evaluable sitting pulse rate data.</population>
        <group_list>
          <group group_id="O1">
            <title>3.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
          </group>
          <group group_id="O2">
            <title>2.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>1.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O8">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate at Dose Decision Point</title>
          <description>Sitting pulse rate was measured at the time that the dose decision was made (dose decision point). Change from baseline in pulse rate was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.</description>
          <population>All participants randomized before the dose decision point who had evaluable sitting pulse rate data.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="35"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.63" spread="7.28"/>
                    <measurement group_id="O2" value="3.43" spread="10.14"/>
                    <measurement group_id="O3" value="2.39" spread="7.88"/>
                    <measurement group_id="O4" value="3.34" spread="9.88"/>
                    <measurement group_id="O5" value="-1.63" spread="8.03"/>
                    <measurement group_id="O6" value="1.91" spread="6.18"/>
                    <measurement group_id="O7" value="1.05" spread="9.44"/>
                    <measurement group_id="O8" value="-0.16" spread="8.07"/>
                    <measurement group_id="O9" value="1.81" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure at Dose Decision Point</title>
        <description>Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at the dose decision point. Change from baseline in DBP was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the time of the decision point was 27.4 weeks.</description>
        <time_frame>Baseline up to 27.4 weeks</time_frame>
        <population>All participants randomized before the dose decision point who had evaluable sitting SBP and DBP data.</population>
        <group_list>
          <group group_id="O1">
            <title>3.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
          </group>
          <group group_id="O2">
            <title>2.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>1.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O8">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at Dose Decision Point</title>
          <description>Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at the dose decision point. Change from baseline in DBP was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the time of the decision point was 27.4 weeks.</description>
          <population>All participants randomized before the dose decision point who had evaluable sitting SBP and DBP data.</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="35"/>
                <count group_id="O9" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.85" spread="12.92"/>
                    <measurement group_id="O2" value="-4.63" spread="15.28"/>
                    <measurement group_id="O3" value="-4.77" spread="11.37"/>
                    <measurement group_id="O4" value="-2.00" spread="9.94"/>
                    <measurement group_id="O5" value="-6.21" spread="19.13"/>
                    <measurement group_id="O6" value="0.40" spread="11.51"/>
                    <measurement group_id="O7" value="1.67" spread="10.18"/>
                    <measurement group_id="O8" value="-2.16" spread="10.62"/>
                    <measurement group_id="O9" value="-0.61" spread="14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="7.47"/>
                    <measurement group_id="O2" value="-1.17" spread="6.32"/>
                    <measurement group_id="O3" value="-1.20" spread="4.67"/>
                    <measurement group_id="O4" value="-0.08" spread="8.00"/>
                    <measurement group_id="O5" value="-3.18" spread="10.13"/>
                    <measurement group_id="O6" value="-0.75" spread="7.99"/>
                    <measurement group_id="O7" value="1.28" spread="4.06"/>
                    <measurement group_id="O8" value="-1.11" spread="6.65"/>
                    <measurement group_id="O9" value="-0.22" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate</title>
        <description>Sitting and standing pulse rate were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as covariate.</description>
        <time_frame>Baseline, 26 weeks, 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable pulse data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate</title>
          <description>Sitting and standing pulse rate were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as covariate.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable pulse data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>beats per minute (bpm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting, 26 Weeks (n=271, 278, 283, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="0.47"/>
                    <measurement group_id="O2" value="1.90" spread="0.47"/>
                    <measurement group_id="O3" value="-0.11" spread="0.46"/>
                    <measurement group_id="O4" value="-0.22" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting, 104 Weeks (n=197, 192, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.53"/>
                    <measurement group_id="O2" value="2.77" spread="0.54"/>
                    <measurement group_id="O3" value="-0.78" spread="0.53"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, 26 Weeks (n=271, 277, 281, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="0.52"/>
                    <measurement group_id="O2" value="2.00" spread="0.52"/>
                    <measurement group_id="O3" value="-0.24" spread="0.51"/>
                    <measurement group_id="O4" value="-0.17" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing, 104 Weeks (n=197, 192, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="0.63"/>
                    <measurement group_id="O2" value="2.50" spread="0.64"/>
                    <measurement group_id="O3" value="-1.06" spread="0.63"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure</title>
        <description>Sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26 weeks, 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable SBP and DBP data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure</title>
          <description>Sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable SBP and DBP data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting SBP, 26 Weeks (n=271, 278, 283, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" spread="0.67"/>
                    <measurement group_id="O2" value="-1.40" spread="0.67"/>
                    <measurement group_id="O3" value="-1.94" spread="0.66"/>
                    <measurement group_id="O4" value="1.12" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP, 104 Weeks (n=197, 192, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.81"/>
                    <measurement group_id="O2" value="1.28" spread="0.82"/>
                    <measurement group_id="O3" value="0.02" spread="0.82"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP, 26 Weeks (n=271, 278, 283, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.43"/>
                    <measurement group_id="O2" value="-0.20" spread="0.43"/>
                    <measurement group_id="O3" value="-1.06" spread="0.42"/>
                    <measurement group_id="O4" value="0.68" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP, 104 Weeks (n=197, 192, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.52"/>
                    <measurement group_id="O2" value="1.40" spread="0.52"/>
                    <measurement group_id="O3" value="-0.36" spread="0.52"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing SBP, 26 Weeks (n=271, 277, 281, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="0.76"/>
                    <measurement group_id="O2" value="-1.72" spread="0.76"/>
                    <measurement group_id="O3" value="-2.54" spread="0.74"/>
                    <measurement group_id="O4" value="0.26" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing SBP, 104 Weeks (n=197, 192, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.92"/>
                    <measurement group_id="O2" value="0.17" spread="0.93"/>
                    <measurement group_id="O3" value="-1.20" spread="0.92"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing DBP, 26 Weeks (n=271, 277, 281, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.48"/>
                    <measurement group_id="O2" value="0.03" spread="0.48"/>
                    <measurement group_id="O3" value="-1.36" spread="0.47"/>
                    <measurement group_id="O4" value="-0.52" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing DBP, 104 Weeks (n=197, 192, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.57"/>
                    <measurement group_id="O2" value="0.36" spread="0.58"/>
                    <measurement group_id="O3" value="-0.67" spread="0.58"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia-corrected QT (QTcF) and PR Interval</title>
        <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
        <time_frame>Baseline, 26 weeks, 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable ECG data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia-corrected QT (QTcF) and PR Interval</title>
          <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and comparator (Sitagliptin, Placebo/Sitagliptin) arms who had evaluable ECG data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>milliseconds (msec)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval, 26 Weeks (n=256, 261, 268, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="0.66"/>
                    <measurement group_id="O2" value="1.60" spread="0.66"/>
                    <measurement group_id="O3" value="0.42" spread="0.65"/>
                    <measurement group_id="O4" value="2.24" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval, 104 Weeks (n=168, 170, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" spread="0.90"/>
                    <measurement group_id="O2" value="3.06" spread="0.90"/>
                    <measurement group_id="O3" value="3.19" spread="0.90"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval, 26 Weeks (n=258, 262, 268, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.86" spread="0.75"/>
                    <measurement group_id="O2" value="-2.44" spread="0.75"/>
                    <measurement group_id="O3" value="-1.31" spread="0.73"/>
                    <measurement group_id="O4" value="1.76" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval, 104 Weeks (n=169, 170, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="0.84"/>
                    <measurement group_id="O2" value="-2.49" spread="0.84"/>
                    <measurement group_id="O3" value="-0.02" spread="0.83"/>
                    <measurement group_id="O4" value="NA">Placebo treatment lasted through 26 weeks. Thus, there are no data for this treatment arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant-reported Outcomes, Impact of Weight on Quality of Life-Lite (IWQoL-Lite)</title>
        <description>The Impact of Weight on Quality of Life-Lite (IWQoL-Lite questionnaire) is an obesity-specific, 31-item questionnaire designed to measure the impact of weight on participants’ quality of life. Items are scored on a 5-point numeric rating scale where 5 = “always true” and 1 = “never true”. Items are summed into 6 scales (physical function [11 items], self-esteem [7 items], sexual life [4 items], public distress [5 items], work [4 items], and total score [31 items]) based on the average for the valid responses on that scale multiplied by the number of items on that scale (rounded to the nearest whole integer). Higher scores indicate lower levels of functioning (negative effects). Scores are linearly transformed to a 0 to 100 scale.</description>
        <time_frame>Baseline, 52 weeks, and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms who had evaluable IWQoL-Lite data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participant-reported Outcomes, Impact of Weight on Quality of Life-Lite (IWQoL-Lite)</title>
          <description>The Impact of Weight on Quality of Life-Lite (IWQoL-Lite questionnaire) is an obesity-specific, 31-item questionnaire designed to measure the impact of weight on participants’ quality of life. Items are scored on a 5-point numeric rating scale where 5 = “always true” and 1 = “never true”. Items are summed into 6 scales (physical function [11 items], self-esteem [7 items], sexual life [4 items], public distress [5 items], work [4 items], and total score [31 items]) based on the average for the valid responses on that scale multiplied by the number of items on that scale (rounded to the nearest whole integer). Higher scores indicate lower levels of functioning (negative effects). Scores are linearly transformed to a 0 to 100 scale.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms who had evaluable IWQoL-Lite data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score, Baseline (n=285, 284, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.41" spread="16.031"/>
                    <measurement group_id="O2" value="82.55" spread="16.952"/>
                    <measurement group_id="O3" value="83.97" spread="16.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score, 52 Weeks (n=237, 252, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.92" spread="14.972"/>
                    <measurement group_id="O2" value="86.31" spread="14.673"/>
                    <measurement group_id="O3" value="86.25" spread="15.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score, 104 Weeks (n=190, 190, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.08" spread="15.555"/>
                    <measurement group_id="O2" value="87.47" spread="15.183"/>
                    <measurement group_id="O3" value="86.93" spread="16.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant-reported Outcomes, EQ-5D</title>
        <description>The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts. The first part allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a three level scale of 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the questionnaire consists of a 100-millimeter visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
        <time_frame>Baseline, 52 weeks, and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms who had evaluable EQ-5D data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participant-reported Outcomes, EQ-5D</title>
          <description>The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts. The first part allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a three level scale of 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the questionnaire consists of a 100-millimeter visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms who had evaluable EQ-5D data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EQ-5D, UK, Baseline (n=285, 281, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.222"/>
                    <measurement group_id="O2" value="0.82" spread="0.223"/>
                    <measurement group_id="O3" value="0.84" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D, UK, 52 Weeks (n=237, 250, 244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.211"/>
                    <measurement group_id="O2" value="0.84" spread="0.208"/>
                    <measurement group_id="O3" value="0.85" spread="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D, UK, 104 Weeks (n=189, 190, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.203"/>
                    <measurement group_id="O2" value="0.86" spread="0.184"/>
                    <measurement group_id="O3" value="0.86" spread="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, Baseline (n=285, 284, 301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.57" spread="15.798"/>
                    <measurement group_id="O2" value="75.35" spread="16.001"/>
                    <measurement group_id="O3" value="76.85" spread="15.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 52 Weeks (n=238, 251, 245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.93" spread="13.352"/>
                    <measurement group_id="O2" value="78.22" spread="13.839"/>
                    <measurement group_id="O3" value="78.79" spread="14.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, 104 Weeks (n=189, 190, 185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.66" spread="13.820"/>
                    <measurement group_id="O2" value="78.52" spread="14.114"/>
                    <measurement group_id="O3" value="81.34" spread="13.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resource Utilization</title>
        <description>The number of visits to the emergency room (ER) is summarized cumulatively.</description>
        <time_frame>Baseline through 52 and 104 weeks</time_frame>
        <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Resource Utilization</title>
          <description>The number of visits to the emergency room (ER) is summarized cumulatively.</description>
          <population>All randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) and active comparator (Sitagliptin) arms.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="302"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>52 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not summarized cumulatively for this outcome measure.</measurement>
                    <measurement group_id="O2" value="NA">Data were not summarized cumulatively for this outcome measure.</measurement>
                    <measurement group_id="O3" value="NA">Data were not summarized cumulatively for this outcome measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data were not summarized cumulatively for this outcome measure.</measurement>
                    <measurement group_id="O2" value="NA">Data were not summarized cumulatively for this outcome measure.</measurement>
                    <measurement group_id="O3" value="NA">Data were not summarized cumulatively for this outcome measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of LY2189265: Area Under the Concentration-Time Curve</title>
        <description>Pharmacokinetic (PK) parameter estimates from LY2189265 concentration data were obtained using a 2-compartment population PK model with first order absorption. Area under the plasma-concentration curve from 0 to 168 hours, steady state (AUC0-168h, ss) of LY2189265 is summarized.</description>
        <time_frame>Baseline through 52 weeks</time_frame>
        <population>Randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) who had blood samples collected for PK assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of LY2189265: Area Under the Concentration-Time Curve</title>
          <description>Pharmacokinetic (PK) parameter estimates from LY2189265 concentration data were obtained using a 2-compartment population PK model with first order absorption. Area under the plasma-concentration curve from 0 to 168 hours, steady state (AUC0-168h, ss) of LY2189265 is summarized.</description>
          <population>Randomized participants in the selected (1.5 mg, 0.75 mg LY2189265) who had blood samples collected for PK assessments.</population>
          <units>nanograms times hours per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13378" spread="6100"/>
                    <measurement group_id="O2" value="7246" spread="3304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibodies to LY2189265</title>
        <description>The number of participants with postbaseline detection of treatment-emergent antidrug LY2189265 antibodies (ADA) is summarized.</description>
        <time_frame>Baseline through 104 weeks</time_frame>
        <population>All randomized participants in the LY2189265 arms who had evaluable ADA data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2189265</title>
            <description>LY2189265 (Dulaglutide): 3.0, 2.0, 1.5, 1.0, 0.75, 0.5, or 0.25 milligrams (mg), subcutaneous (SC), once weekly for up to 104 weeks.
Placebo: tablet, administered orally, once daily for up to 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Antibodies to LY2189265</title>
          <description>The number of participants with postbaseline detection of treatment-emergent antidrug LY2189265 antibodies (ADA) is summarized.</description>
          <population>All randomized participants in the LY2189265 arms who had evaluable ADA data. If there were no data after the date of randomization, the endpoint was considered missing.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="698"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adjudicated Pancreatitis at 104 Weeks</title>
        <description>The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 104 weeks</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>3.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
          </group>
          <group group_id="O2">
            <title>2.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>1.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O8">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O10">
            <title>Placebo/Sitagliptin (26 Weeks Through 104 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Pancreatitis at 104 Weeks</title>
          <description>The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>All randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="302"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="315"/>
                <count group_id="O9" value="177"/>
                <count group_id="O10" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adjudicated Cardiovascular Events at 104 Weeks</title>
        <description>Data on any new cardiovascular (CV) event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through 104 weeks</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>3.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
          </group>
          <group group_id="O2">
            <title>2.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O4">
            <title>1.0 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg LY2189265</title>
            <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
          </group>
          <group group_id="O8">
            <title>Sitagliptin</title>
            <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo/Sitagliptin (Baseline Through 26 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
          <group group_id="O10">
            <title>Placebo/Sitagliptin (26 Weeks Through 104 Weeks)</title>
            <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Cardiovascular Events at 104 Weeks</title>
          <description>Data on any new cardiovascular (CV) event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
          <population>All randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="302"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="315"/>
                <count group_id="O9" value="177"/>
                <count group_id="O10" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants With Any CV Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants With a Fatal CV Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants With a Non-fatal CV Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>3.0 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.1 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.1 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.1 weeks)</description>
        </group>
        <group group_id="E2">
          <title>2.0 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 20.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 20.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 20.4 weeks)</description>
        </group>
        <group group_id="E3">
          <title>1.5 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
        <group group_id="E4">
          <title>1.0 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
        </group>
        <group group_id="E5">
          <title>0.75 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally, for 104 weeks</description>
        </group>
        <group group_id="E6">
          <title>0.5 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 27.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 27.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 27.4 weeks)</description>
        </group>
        <group group_id="E7">
          <title>0.25 mg LY2189265</title>
          <description>LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly up to decision point (maximum exposure duration of 24.4 weeks)
Placebo: tablet, administered orally, once daily up to decision point (maximum exposure duration of 24.4 weeks)
Metformin: at least 1500 milligrams per day (mg/day), administered orally up to decision point (maximum exposure duration of 24.4 weeks)</description>
        </group>
        <group group_id="E8">
          <title>Sitagliptin</title>
          <description>Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
        <group group_id="E9">
          <title>Placebo/Sitagliptin (Baseline Through 104 Weeks)</title>
          <description>Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
Placebo: tablet, administered orally, once daily for 26 weeks
Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily, for 78 weeks
Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="302"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="315"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <description>Event resulted in death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Femoral hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <description>Event resulted in death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Injection site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Intervertebral disc injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcitonin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer stage iii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Non-secretory adenoma of pituitary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <description>Event resulted in death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <description>Event resulted in death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Stevens-johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="252" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="255" subjects_at_risk="302"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="239" subjects_at_risk="315"/>
                <counts group_id="E9" subjects_affected="138" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="17" subjects_affected="10" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="18" subjects_affected="15" subjects_at_risk="302"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="26" subjects_affected="21" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="24" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="12" subjects_affected="11" subjects_at_risk="315"/>
                <counts group_id="E9" events="6" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="13" subjects_affected="12" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="10" subjects_affected="9" subjects_at_risk="315"/>
                <counts group_id="E9" events="12" subjects_affected="10" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="22" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="74" subjects_affected="50" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="53" subjects_affected="36" subjects_at_risk="302"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" events="30" subjects_affected="18" subjects_at_risk="315"/>
                <counts group_id="E9" events="23" subjects_affected="15" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="25" subjects_affected="18" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="23" subjects_affected="19" subjects_at_risk="302"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="17" subjects_affected="16" subjects_at_risk="315"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="304"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="9" subjects_affected="9" subjects_at_risk="315"/>
                <counts group_id="E9" events="8" subjects_affected="7" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="315"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="98" subjects_affected="53" subjects_at_risk="304"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="62" subjects_affected="44" subjects_at_risk="302"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" events="27" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E9" events="15" subjects_affected="9" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="62" subjects_affected="41" subjects_at_risk="304"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="43" subjects_affected="25" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="315"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="315"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="315"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="10" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="315"/>
                <counts group_id="E9" events="8" subjects_affected="7" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="22" subjects_affected="18" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="15" subjects_affected="14" subjects_at_risk="315"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="64" subjects_affected="43" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="96" subjects_affected="48" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="72" subjects_affected="47" subjects_at_risk="315"/>
                <counts group_id="E9" events="44" subjects_affected="25" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="22" subjects_affected="15" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="14" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="315"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="34" subjects_affected="22" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="30" subjects_affected="22" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="24" subjects_affected="21" subjects_at_risk="315"/>
                <counts group_id="E9" events="8" subjects_affected="7" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="26" subjects_affected="21" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="25" subjects_affected="21" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="22" subjects_affected="19" subjects_at_risk="315"/>
                <counts group_id="E9" events="21" subjects_affected="14" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="9" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="8" subjects_affected="6" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Blood calcitonin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="21" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="16" subjects_affected="15" subjects_at_risk="315"/>
                <counts group_id="E9" events="9" subjects_affected="5" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="31" subjects_affected="29" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="23" subjects_affected="17" subjects_at_risk="302"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="315"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="30" subjects_affected="30" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="38" subjects_affected="38" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="49" subjects_affected="49" subjects_at_risk="315"/>
                <counts group_id="E9" events="28" subjects_affected="28" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="19" subjects_affected="15" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="22" subjects_affected="19" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="16" subjects_affected="14" subjects_at_risk="315"/>
                <counts group_id="E9" events="11" subjects_affected="7" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="28" subjects_affected="21" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="32" subjects_affected="28" subjects_at_risk="302"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="24" subjects_affected="19" subjects_at_risk="315"/>
                <counts group_id="E9" events="9" subjects_affected="9" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="20" subjects_affected="18" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="20" subjects_affected="14" subjects_at_risk="315"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="53" subjects_affected="29" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="76" subjects_affected="27" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="33" subjects_affected="26" subjects_at_risk="315"/>
                <counts group_id="E9" events="17" subjects_affected="12" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="315"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="24" subjects_affected="19" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="26" subjects_affected="17" subjects_at_risk="315"/>
                <counts group_id="E9" events="7" subjects_affected="6" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

